You are here

Profiles and Perspectives

Comment

Discuss
June 2015
Proceedings: Human Leukocyte Antigen Haplo-Homozygous Induced Pluripotent Stem Cell Haplobank Modeled After the California Population: Evaluating Matching in a Multiethnic and Admixed Population
Derek James Pappas, Pierre-Antoine Gourraud, Caroline Le Gall, Julie Laurent, Alan Trounson, Natalie DeWitt, Sohel Talib
Stem Cells Trans Med 2015; 4:413-418; doi:10.5966/sctm.2015-0052

This study developed a new model for evaluating an induced pluripotent stem cell (iPSC) haplobank based on demographic and immunogenetic characteristics reflecting California. Creation of a haplobank of iPSC lines homozygous for a variety of human leukocyte antigen (HLA) types, representative of different geographic populations and ethnic groups, could simplify HLA matching and provide matches for reasonable percentages of target populations and extend iPSC-derived therapies beyond the autologous setting.

June 2015
Fetal Endothelial and Mesenchymal Progenitors From the Human Term Placenta: Potency and Clinical Potential
Abbas Shafiee, Nicholas M. Fisk, Dietmar W. Hutmacher, Kiarash Khosrotehrani, Jatin Patel
Stem Cells Trans Med 2015; 4:419-423; first published on March 13, 2015; doi:10.5966/sctm.2014-0224

The importance of fetal microchimerism to the field of fetal stem cell biology and issues of maternal contamination from perinatal tissues is highlighted and specific isolation strategies to overcome these translational obstacles are discussed.

April 2015
Proceedings: Moving Toward Cell-Based Therapies for Liver Disease
Lisa C. Kadyk, Lila R. Collins, Neil J. Littman, and Maria T. Millan
Stem Cells Trans Med 2015; 4:207-210; first published on January 30, 2015; doi:10.5966/sctm.2014-0276

Liver cell transplantation holds potential for the treatment of liver failure, end-stage liver disease, and liver-based inborn errors of metabolism; however, the field is in search of a suitable cell therapeutic.

 
April 2015
Proceedings: The SEED Grant Program: A Brief Synopsis of the Outcomes and Impact of CIRM’s First Research Initiative
Kelly A. Shepard
Stem Cells Trans Med 2015; 4:211-216; first published on February 2, 2015; doi:10.5966/sctm.2014-0299

In late 2006, the California Institute for Regenerative Medicine (CIRM) launched its first major research initiative to catalyze the nascent field of human embryonic stem cell (hESC) research. The Scientific Excellence through Exploration and Development (SEED) program attracted new investigators from all stages of their career to the field of hESC research.

 
April 2015
Enabling Consistency in Pluripotent Stem Cell-Derived Products for Research and Development and Clinical Applications Through Material Standards
Anna French, Christopher Bravery, James Smith, et. al.
Stem Cells Trans Med 2015; 4:217-223; first published on February 3, 2015; doi:10.5966/sctm.2014-0233

This article discusses the need for reference materials, potential challenges faced by human pluripotent stem cell-derived products, and possible approaches to alleviating concerns about consistency and reproducibility in their production.

 
April 2015
Clinical Research Skills Development Program in Cell-Based Regenerative Medicine
Ivonne Hernandez Schulman, Viky Suncion, Vasileios Karantalis, Wayne Balkan, Joshua M. Hare, and for the Cardiovascular Cell Therapy Research Network
Stem Cells Trans Med 2015; 4:118-122; first published on December 29, 2014; doi:10.5966/sctm.2014-0144

The current lack of training for physicians in cell-based therapy combined with the sharply increasing practice of regenerative medicine is concerning for a number of reasons, namely potential harm to patients and avoidable conflicts between governmental regulatory agencies and physicians.

 
April 2015
The DISCUSS Project: Revised Points to Consider for the Derivation of Induced Pluripotent Stem Cell Lines From Previously Collected Research Specimens
Geoffrey P. Lomax, Sara Chandros Hull, and Rosario Isasi
Stem Cells Trans Med 2015; 4:123-129; first published on January 5, 2015; doi:10.5966/sctm.2014-0192

The Deriving Induced Stem Cells Using Stored Specimens (DISCUSS) project is a consensus-building initiative designed to consider how human somatic cells obtained under general biomedical research protocols can be used in induced pluripotent stem cell (iPSC) derivation.

April 2015
Manufacturing Road Map for Tissue Engineering and Regenerative Medicine Technologies
Joshua Hunsberger, Ola Harrysson, Rohan Shirwaiker, Binil Starly, Richard Wysk, Paul Cohen, Julie Allickson, James Yoo, and Anthony Atala
Stem Cells Trans Med 2015; 4:130-135; first published on January 9, 2015; doi:10.5966/sctm.2014-0254

The 2014 Regenerative Medicine Foundation Annual Conference had a vision of assisting with translating tissue engineering and regenerative medicine-based technologies by assembling leaders in the field to cover critical areas, including regulatory pathways for regenerative medicine therapies, strategic partnerships, resource coordination, developing standards, government support, industry priorities, biobanking, and new technologies.

April 2015
Proceedings: Debilitating Eye Diseases
Ingrid W. Caras, Neil Littman, and Arie Abo
Stem Cells Trans Med 2014; 3:1393-1397; first published on November 6, 2014; doi:10.5966/sctm.2014-0221

Debilitating eye diseases such as age-related macular degeneration and retinitis pigmentosa currently represent a large unmet medical need that could potentially be addressed by stem cell therapy.

April 2015
Wrongful Termination: Lessons From the Geron Clinical Trial
Christopher Thomas Scott, and David Magnus
Stem Cells Trans Med 2014; 3:1398-1401; first published on October 8, 2014; doi:10.5966/sctm.2014-0147

This study examines the major ethical and social questions raised by the cancellation of the 2010 phase I clinical trial of a human embryonic stem cell-based therapy for spinal cord injury. The study provides recommendations for institutional review boards and clinical sites as they deliberate approvals of early-phase trials in frontier medicine.

Pages